Redigerer Polycystisk ovariesyndrom (avsnitt)

== Litteratur ==
# Monarch Disease Ontology release 2018-06-29sonu — 2018-06-29 — 2018. 
# ↑ ''Azziz R.'' Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature  // Journal of Clinical Endocrinology & Metabolism : journal. — 2006. — March (vol. 91, no. 3). — P. 781—785. — doi:10.1210/jc.2005-2153. — <nowiki>PMID 16418211</nowiki>.
# ↑ ''Carmina E.'' Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. // Minerva ginecologica : journal. — 2004. — February (vol. 56, no. 1). — P. 1—6. — <nowiki>PMID 14973405</nowiki>.
# ↑ ''Hart R., Hickey M., Franks S.'' Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome  // Best Practice & Research Clinical Obstetrics & Gynaecology : journal. — 2004. — October (vol. 18, no. 5). — P. 671—683. — doi:10.1016/j.bpobgyn.2004.05.001. — <nowiki>PMID 15380140</nowiki>.
# ↑ ''Christine Cortet-Rudelli, Didier Dewailly.'' Diagnosis of Hyperandrogenism in Female Adolescents. ''Hyperandrogenism in Adolescent Girls''. Armenian Health Network, Health.am (Sep 21 2006). 
# ↑ ''Nafiye Y., Sevtap K., Muammer D., Emre O., Senol K., Leyla M.'' The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome  // Fertil. Steril. : journal. — 2010. — April (vol. 93, no. 6). — P. 1864—1869. — doi:10.1016/j.fertnstert.2008.12.024. — <nowiki>PMID 19171332</nowiki>.
# ↑ ''Fruzzetti F., Bersi C., Parrini D., Ricci C., Genazzani A.R.'' Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome  // Fertil. Steril. : journal. — 2002. — May (vol. 77, no. 5). — P. 936—944. — <nowiki>PMID 12009347</nowiki>.
# ↑ ''Fulghesu A.M., Ciampelli M., Guido M., et al.'' Role of opioid tone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease  // Metab. Clin. Exp. : journal. — 1998. — February (vol. 47, no. 2). — P. 158—162. — <nowiki>PMID 9472963</nowiki>.
# ↑ ''Gogokhiia N.A., Natmeladze K.M., Mikaberidze KhL.'' [Study of dopamine effect on neuroendocrine disorders during polycystic-ovary syndrome using the method of enzyme-linked immunosorbent analysis (ELISA)]  // Georgian Med News. — 2005. — № 124—125. — С. 65—7. — <nowiki>PMID 16148382</nowiki>.
# ↑ ''Hernández I., Parra A., Méndez I., et al.'' Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome  // Arch. Med. Res. : journal. — 2000. — Vol. 31, no. 2. — P. 216—222. — <nowiki>PMID 10880731</nowiki>.
# ↑ ''Zironi C., Pantaleoni M., Zizzo G., Coletta F., Velardo A.'' [Evaluation of dopaminergic activity of the hypothalamus in patients with polycystic ovarian syndrome]  // Minerva Ginecol. — 1991. — oktober (т. 43, № 10). — С. 443—447. — <nowiki>PMID 1685015</nowiki>.
# ↑ ''Unfer V, Carlomagno G, Dante G, Facchinetti F.'' Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509-15
# ''Levine, J.'' (1997). Controlled trials of inositol in psychiatry. ''European neuropsychopharmacology,'' ''7''(2), 147-155.
# ''Palatnik, A., Frolov, K., Fux, M., & Benjamin, J''. (2001). Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. ''Journal of clinical psychopharmacology'', ''21''(3), 335-339.
# ''Levine, J., Barak, Y., Gonzalves, M., Szor, H., Elizur, A., Kofman, O., & Belmaker, R. H.'' (1995). Double-blind, controlled trial of inositol treatment of depression. ''American Journal of Psychiatry'', ''152''(5), 792-793.
# ''Giordano, D., Corrado, F., Santamaria, A., Quattrone, S., Pintaudi, B., Di Benedetto, A., & D’Anna, R.'' (2011). Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. ''Menopause'', ''18''(1), 102-104.
# ''Santamaria, A., Giordano, D., Corrado, F., Pintaudi, B., Interdonato, M. L., Vieste, G. D.,  & D’Anna, R.'' (2012). One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. ''Climacteric'', ''15''(5), 490-495.
# ''Clements Jr, R. S., & Darnell, B.'' (1980). Myo-inositol content of common foods: development of a high-myo-inositol diet. ''The American journal of clinical nutrition,'' ''33''(9), 1954-1967.